| Literature DB >> 29491774 |
Ghulam Abbas1,2, Muhammad Hanif1, Mahtab Ahmad Khan1.
Abstract
Aim of the present work was to develop alginate raft forming tablets for controlled release pantoprazole sodium sesquihydrate (PSS). Box behnken design was used to optimize 15 formulations with three independent and three dependent variables. Physical tests of all formulations were within pharmacopoeial limits. Raft was characterized by their strength, thickness, resilience, acid neutralizing capacity, floating lag time and total floating time. Raft strength, thickness and resilience of optimized formulation AR9 were 7.43 ± 0.019 g, 5.8 ± 0.245 cm and greater than 480 min, respectively. Buffering and neutralizing capacity were 11.2 ± 1.01 and 6.5 ± 0.56 meq, respectively. Dissolution studies were performed by using simulated gastric fluid pH 1.2 and cumulative percentage release of optimized formulation AR9 was found 98%. First order release kinetics were followed and non-fickian diffusion was observed as value of n was greater than 0.45 in korsmeyer-peppas model. PSS, polymers, tablets and rafts were further characterized by Fourier transform infrared spectroscopy (FTIR), X-ray diffractometry (XRD) and differential scanning calorimetry (DSC). FTIR spectra of PSS, polymers and raft of optimized formulation AR9 showed peaks at 3223.09, 1688.17, 1586.67, 1302.64 and 1027.74 cm-1 due to -OH stretching, ester carbonyl group (C=O) stretching, existence of water and carboxylic group in raft, C-N stretching and -OH bending vibration showed no interaction between them. XRD showed diffraction lines indicates crystalline nature of PSS. DSC thermogram showed endothermic peaks at 250 °C for PSS. The developed raft was suitable for controlled release delivery of PSS.Entities:
Keywords: DSC; FTIR; Sodium alginate; XRD; box-behnken design; in vitro drug release; raft resilience
Year: 2016 PMID: 29491774 PMCID: PMC5812168 DOI: 10.1080/15685551.2016.1231046
Source DB: PubMed Journal: Des Monomers Polym ISSN: 1385-772X Impact factor: 2.650
Independent and dependent variables and constrains in box-behnken design.
| Variables | Level | Constrains | ||
|---|---|---|---|---|
| −1 | 0 | +1 | ||
| Independent | ||||
| 10 | 25 | 40 | In the range | |
| 6 | 10 | 14 | In the range | |
| 20 | 30 | 40 | In the range | |
| Dependent | ||||
| 20–40 | ||||
| 40–60 | ||||
| 80–100 | ||||
Composition of alginate raft forming tablets.
| Formulation code | PSS (mg) | Sodium alginate (mg) | HPMC K100M (mg) | Sodium bicarbonate (mg) | Citric acid (mg) | Calcium carbonate (mg) | Total weight (mg) |
|---|---|---|---|---|---|---|---|
| AR1 | 40 | 40 | 56 | 120 | 60 | 84 | 400 |
| AR2 | 40 | 100 | 40 | 120 | 60 | 40 | 400 |
| AR3 | 40 | 160 | 40 | 100 | 50 | 10 | 400 |
| AR4 | 40 | 40 | 40 | 80 | 40 | 160 | 400 |
| AR5 | 40 | 100 | 40 | 120 | 60 | 40 | 400 |
| AR6 | 40 | 120 | 56 | 100 | 50 | 34 | 400 |
| AR7 | 40 | 100 | 24 | 80 | 40 | 116 | 400 |
| AR8 | 40 | 140 | 24 | 120 | 60 | 16 | 400 |
| AR9 | 40 | 160 | 40 | 80 | 40 | 40 | 400 |
| AR10 | 40 | 100 | 24 | 140 | 70 | 26 | 400 |
| AR11 | 40 | 40 | 24 | 120 | 60 | 116 | 400 |
| AR12 | 40 | 100 | 40 | 120 | 60 | 40 | 400 |
| AR13 | 40 | 80 | 56 | 140 | 70 | 14 | 400 |
| AR14 | 40 | 40 | 40 | 160 | 80 | 40 | 400 |
| AR15 | 40 | 100 | 56 | 80 | 40 | 84 | 400 |
Observed responses for alginate rafts forming tablets (n = 6).
| Formulation code | Independent variables | Dependent variables | ||||
|---|---|---|---|---|---|---|
| AR1 | 10 | 14 | 30 | 24.54 ± 0.011 | 49.11 ± 0.023 | 79.78 ± 0.091 |
| AR2 | 25 | 10 | 30 | 35.43 ± 0.023 | 60.98 ± 0.982 | 95.67 ± 0.095 |
| AR3 | 40 | 10 | 25 | 31.12 ± 0.123 | 53.89 ± 0.312 | 90.12 ± 0.011 |
| AR4 | 10 | 10 | 20 | 41.23 ± 0.093 | 64.65 ± 0.256 | 93.11 ± 0.034 |
| AR5 | 25 | 10 | 30 | 36.87 ± 0.034 | 59.92 ± 0.095 | 95.23 ± 0.711 |
| AR6 | 30 | 14 | 25 | 30.99 ± 0.081 | 57.78 ± 0.367 | 79.12 ± 0.098 |
| AR7 | 25 | 6 | 20 | 47.76 ± 0.456 | 72.21 ± 0.087 | 92.68 ± 0.458 |
| AR8 | 35 | 6 | 30 | 47.34 ± 0.125 | 75.29 ± 0.087 | 94.01 ± 0.059 |
| AR9 | 40 | 10 | 20 | 36.50 ± 0.087 | 58.89 ± 0.054 | 98.32 ± 0.911 |
| AR10 | 25 | 6 | 35 | 44.42 ± 0.056 | 71.12 ± 0.178 | 95.32 ± 0.081 |
| AR11 | 10 | 6 | 30 | 45.67 ± 0.049 | 68.34 ± 0.034 | 95.67 ± 0.487 |
| AR12 | 25 | 10 | 30 | 34.44 ± 0.086 | 64.55 ± 0.031 | 94.42 ± 0.043 |
| AR13 | 20 | 14 | 35 | 25.65 ± 0.056 | 46.65 ± 0.012 | 79.35 ± 0.045 |
| AR14 | 10 | 10 | 40 | 33.99 ± 0.014 | 58.87 ± 0.054 | 94.45 ± 0.123 |
| AR15 | 25 | 14 | 20 | 21.53 ± 0.987 | 46.55 ± 0.654 | 81.98 ± 0.014 |
Figure 1.3D response surface graph showing effects of sodium alginate (X 1), HPMC K100M (X 2) and sodium bicarbonate (X 3) on (A) % drug release at 2 h (Y 2), (B) % drug release at 4 h (Y 4) and (C) % drug release at 8 h (Y 8).
Disintegration time of tablets and strength, weight, volume and thickness of raft (n = 6).
| Formulation code | Disintegration time (s) | Raft strength (g) | Raft weight (g) | Raft volume (ml) | Raft thickness (cm) |
|---|---|---|---|---|---|
| AR1 | 54 | 3.19 ± 0.067 | 1.39 ± 0.012 | 5.5 ± 0.15 | 3.5 ± 0.045 |
| AR2 | 63 | 5.29 ± 0.039 | 1.84 ± 0.010 | 7.2 ± 0.05 | 4.5 ± 0.216 |
| AR3 | 57 | 7.31 ± 0.012 | 2.10 ± 0.029 | 8.9 ± 0.05 | 5.5 ± 0.136 |
| AR4 | 55 | 3.10 ± 0.097 | 1.32 ± 0.011 | 5.7 ± 0.25 | 3.9 ± 0.048 |
| AR5 | 67 | 5.20 ± 0.013 | 1.85 ± 0.010 | 7.5 ± 0.15 | 4.7 ± 0.193 |
| AR6 | 65 | 7.30 ± 0.067 | 2.20 ± 0.013 | 8.4 ± 0.35 | 5.6 ± 0.085 |
| AR7 | 64 | 5.59 ± 0.019 | 1.79 ± 0.011 | 7.3 ± 0.25 | 4.7 ± 0.212 |
| AR8 | 63 | 7.32 ± 0.047 | 2.00 ± 0.015 | 8.7 ± 0.15 | 5.5 ± 0.110 |
| AR9 | 64 | 7.11 ± 0.010 | 2.19 ± 0.010 | 8.8 ± 0.05 | 5.8 ± 0.245 |
| AR10 | 57 | 5.10 ± 0.062 | 1.80 ± 0.034 | 7.0 ± 0.45 | 4.3 ± 0.021 |
| AR11 | 53 | 3.11 ± 0.069 | 1.23 ± 0.011 | 5.9 ± 0.85 | 3.8 ± 0.125 |
| AR12 | 57 | 5.78 ± 0.067 | 1.79 ± 0.032 | 7.9 ± 0.14 | 4.9 ± 0.211 |
| AR13 | 54 | 5.61 ± 0.076 | 1.90 ± 0.021 | 7.8 ± 0.25 | 4.7 ± 0.745 |
| AR14 | 53 | 3.15 ± 0.013 | 1.11 ± 0.012 | 5.5 ± 0.15 | 3.4 ± 0.236 |
| AR15 | 59 | 5.36 ± 0.063 | 1.92 ± 0.056 | 7.6 ± 0.15 | 4.6 ± 0.045 |
Buffering capacity, neutralizing capacity, resilience, FLT and TFT of raft forming tablets (n = 6).
| Formulation code | pH After 4 min | pH After 20 min | Buffering capacity (meq) | Neutralizing capacity (meq) | Raft resilience (min) | FLT (s) | TFT (h) |
|---|---|---|---|---|---|---|---|
| AR1 | 4.1 | 5.4 | 11.5 ± 1.01 | 6.9 ± 0.57 | >480 | 51 | >8 |
| AR2 | 4.2 | 5.5 | 11.0 ± 1.04 | 5.5 ± 0.49 | >480 | 52 | >8 |
| AR3 | 5.5 | 6.7 | 15.7 ± 1.05 | 7.5 ± 0.31 | >480 | 51 | >8 |
| AR4 | 3.5 | 4.2 | 10.3 ± 1.81 | 6.8 ± 0.55 | >480 | 54 | >8 |
| AR5 | 4.6 | 5.6 | 13.9 ± 1.07 | 7.6 ± 0.10 | >480 | 52 | >8 |
| AR6 | 4.4 | 5.2 | 11.5 ± 1.05 | 5.7 ± 0.49 | >480 | 49 | >8 |
| AR7 | 3.2 | 4.6 | 10.6 ± 1.91 | 6.8 ± 0.23 | >480 | 48 | >8 |
| AR8 | 4.2 | 5.8 | 12.5 ± 1.41 | 6.7 ± 0.26 | >480 | 50 | >8 |
| AR9 | 3.8 | 4.9 | 11.2 ± 1.01 | 6.5 ± 0.56 | >480 | 55 | >8 |
| AR10 | 5.7 | 6.9 | 14.7 ± 1.05 | 7.6 ± 0.12 | >480 | 54 | >8 |
| AR11 | 4.1 | 5.0 | 10.90 ± 1.30 | 4.9 ± 0.49 | >480 | 49 | >8 |
| AR12 | 4.6 | 5.2 | 13.69 ± 1.04 | 7.8 ± 0.16 | >480 | 56 | >8 |
| AR13 | 5.0 | 6.3 | 12.10 ± 1.10 | 6.9 ± 0.59 | >480 | 51 | >8 |
| AR14 | 5.3 | 6.5 | 10.20 ± 1.31 | 5.8 ± 0.49 | >480 | 53 | >8 |
| AR15 | 3.4 | 4.3 | 12.70 ± 1.21 | 7.0 ± 0.34 | >480 | 50 | >8 |
Figure 2.Drug release profile of pantoprazole sodium sesquihydrate from alginate rafts (n = 6).
Figure 3.FTIR spectra of (A) PSS, (B) sodium alginate, (C) HPMC K100M and (D) alginate raft of optimized formulation AR9.
Figure 4.DSC thermograms of (A) PSS, (B) sodium alginate, (C) HPMC K100M and (D) tablet of optimized formulation AR9 and (E) alginate raft of optimized formulation AR9.
Figure 5.XRD of (A) PSS, (B) sodium alginate, (C) HPMC K100M and (D) tablet of optimized formulation AR9 and (E) alginate raft of optimized formulation AR9.